VR Adviser LLC Takes $37.74 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

VR Adviser LLC acquired a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,295,319 shares of the company's stock, valued at approximately $37,735,000. Upstream Bio comprises approximately 2.6% of VR Adviser LLC's holdings, making the stock its 14th biggest position. VR Adviser LLC owned approximately 4.28% of Upstream Bio at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $117,977,000. Orbimed Advisors LLC bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $93,603,000. Decheng Capital LLC bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $54,010,000. TCG Crossover Management LLC bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $44,856,000. Finally, Enavate Sciences GP LLC bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $40,438,000.

Upstream Bio Stock Performance

UPB stock traded down $0.15 on Friday, reaching $9.16. The company's stock had a trading volume of 284,858 shares, compared to its average volume of 327,321. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46. The firm has a fifty day moving average of $8.04 and a two-hundred day moving average of $12.36.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million. On average, equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.